Tuesday, October 05, 2021 4:14:00 PM
Name and Principal Position
Dr. Cameron Durrant
Chairman and Chief Executive Officer
Dr. Dale Chappell
Chief Scientific Officer
Dr. Adrian Kilcoyne
Chief Medical Officer
Edward Jordon
Chief Commercial Officer
Number of Shares Underlying Grant (#)(1)
17,660 22,626 5,863 4,966
4th Quarter Base Salary Paid in Stock Options (percentage of quarterly amount)
$79,959 (50%) $102,433 (100%) $26,646 (25%) $22485 (25%)
(1) All options granted have an exercise price equal to $5.93, the closing price of Humanigen’s common stock on the September 30, 2021 grant date, and vest in three ratable installments on each of October 31, 2021, November 30, 2021 and December 31, 2021.
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM